Proton Pump Inhibitors Versus H2-Receptor Antagonists for the Treatment of Erosive Gastroesophageal Reflux Disease: A Cost-Comparative Study

Clinicians pair CD20×CD3 bispecifics with radiotherapy in relapsed B‑cell lymphoma, but data stay sparse—early safety signals prompt trials.

“I think there’s not a lot of information as to what the process is for individuals who have questions about that,” explains Kerry Rogers, MD.

Across 29,132 surgically treated T1 cases, lymph node metastasis hit 19.2% under age 50 vs 11.1% at 50 and older.

Medicare's cell and gene therapy payment gap remains, with hospitals absorbing costs as insurers limit coverage.

Congress's Mental Health TALK SAFE Act could expand telepsychiatry access by establishing permanent telehealth prescribing and licensing rules.

CDC data show cancer deaths declining as lung cancer treatment and detection advance, with new KRAS-targeted therapies showing early promise.

Nonadherence to semaglutide for obesity worsened once out-of-pocket costs passed roughly $75 per 30-day supply among commercially insured adults.

At a Stakeholder Interchange convened by The American Journal of Managed Care® in Houston, Texas, oncologists and pharmacists from academic and community practices debated how teclistamab- and talquetamab-based regimens stack up against CAR T-cell therapy in second-line multiple myeloma, and what it will take—staffing, caregiver support, hospital partnerships, and payer buy-in—to move step-up dosing out of the hospital and into the clinic.